Source: People's Daily Health Client Wang Zhenya
A small pill, a large CT, a pacemaker, and an immune agent coagulate the painstaking efforts of many scientists and protect the health of 1.4 billion Chinese people.
For the sake of national health, medical technology innovation is still what everyone wants and what the people expect. The People's Daily health client interviewed 8 senior executives of medical companies at home and abroad to listen to their research and judgment on how to make the innovation of medicine and pharmaceutical equipment "like a tiger".
Takeda Shan Kunihiro:
Conform to the trend of high-quality development and benefit more patients
Takeda China President Shan Guohong
Takeda Pharmaceutical is a global biopharmaceutical company with a history of continuous innovation for more than 240 years. In 2017, Shan Guohong was appointed as the president of Takeda China, and in the past 5 years, Shan Guohong has led Takeda China to experience the progress of the entire industry towards high-quality development, and Takeda China has also achieved accelerated transformation and continued to focus on innovative China development strategy.
Shan Guohong told the People's Daily health client that in recent years, one of the core goals of a series of measures related to the development of the medical and health industry promoted by the state is to improve quality and fair access, so that the people can enjoy the fruits of high-quality development through fair opportunities. This policy orientation will remain in 2022. As a multinational company, it is possible to follow the trend.
How will Takeda Pharmaceutical be promising in China? The answer is to accelerate the push for more innovative medicines to reach patients. Shan Guohong introduced that in 2022, Takeda China will further implement the five-year development plan and list more than 15 innovative drugs in China by 2025. For example, at this stage, there are two innovative products in the field of lung cancer: Mobocertinib and Buguetinib tablets, and are actively promoting the process of domestic approval and listing. The vilasidase α for injectable drugs for rare diseases is scheduled to be commercially available in February for the benefit of patients.
Talking about how to break the innovation track of tumor drugs? Shan Guohong said, "Innovation oriented to real clinical value is the foundation of medical and health enterprises. He believes that the first thing to do is to find clinically valuable and differentiated innovations and benchmark global innovation standards. Second, we must encourage multinational pharmaceutical companies and Chinese innovative enterprises to carry out more diversified and in-depth cooperation.
China is one of Takeda's most important strategic markets in the world, and on the occasion of the New Year, Shan Guohong said, "Takeda is looking forward, and by fiscal year 2031, China will become Takeda's second largest market in the world." ”
Boston Scientific Zhang Jun:
Accelerate the review and approval of medical devices, from "following" to "leading"
Jun Zhang, President of Boston Scientific Greater China
Boston Scientific is a globally growing innovative medical enterprise, and 2022 is the 25th anniversary of Boston Scientific's entry into the Chinese market and the 25th year of rapid development of China's medical device industry. Zhang Jun, President of Boston Scientific Greater China, led the team to witness and personally experience the historic development stage of China's innovative medical device industry from "following" to "leading".
Zhang Jun told the People's Daily health client that accelerating the review and approval of medical devices, the listing license holder system and a series of favorable policies to promote medical innovation have further released the vitality of medical device innovation and stimulated the rapid improvement of enterprises' independent innovation capabilities, which is the key to the innovation of the medical device industry, from "following the run" to "leading".
The Chinese device market is already the second largest market outside the United States, growing at double digits every year. In addition to policy, "building an ecosystem" is Boston Scientific's industry-leading strategy. Boston Scientific and the hospital cooperated to explore the establishment of pain centers, set up optimized diagnosis and treatment processes, make the treatment process clear and standardized, and improve the efficiency of hospital diagnosis and treatment and patient satisfaction.
In Zhang Jun's view, medical innovation takes solving the medical needs of doctors and patients as the essence, and providing safe, effective and appropriate medical solutions can fully reflect the value and vitality of innovation. To achieve the unfinished need for "effective innovation" in order to promote the innovation and upgrading of the entire industry.
To this end, Boston Scientific is also focusing on the need for advanced medical technology for primary care physicians. With the help of emerging technical means such as 5G and digitalization, Boston Scientific has continuously tried more flexible professional education methods, through 5G remote training, remote surgical teaching and mobile education buses, etc., to further sink high-quality medical services, improve the level of medical technology in the county, and help patients not leave the county with serious illness.
Siemens Healthcare Wang Tao:
The collection of enterprises has forced enterprises to turn to innovative drugs and innovative pharmaceutical equipment research and development investment
Wang Tao, Vice President, Marketing and Corporate Communications, Siemens Healthcare Greater China
In the face of policies such as high-value medical consumables collection and medical insurance, how will the multinational instrument Siemens Medical carry out local innovation and look for development opportunities?
In Wang Tao's view, collection and collection are both opportunities and challenges for pharmaceutical and equipment enterprises. She believes that in the future, collection and procurement will also be normalized and institutionalized. The collected medicinal devices are pharmaceutical devices with large demand from patients and mature clinical practices, and they are also relatively homogeneous products with serious homogenization. The collection of enterprises to turn to innovative drugs, innovative pharmaceutical equipment research and development investment, the development of new technologies, new processes, research and development of innovative products.
In the face of opportunities and challenges, Siemens Healthcare has found the key to "breaking the game" in China. Wang Tao told the Health Times reporter that in order to achieve the final victory on the homogenized track, it needs both "explosive power" and "staying power", both first-class innovation ability, and stability and expressiveness that can withstand the test of the market.
Siemens Healthcare has seen the direction of future innovation: intelligent surgical robots, 5G telemedicine, artificial intelligence. For example, Siemens Healthers' interventional surgical robots are expected to be available in mid-2022. The company's 5G remote technology has been deployed in more than 200 hospitals, with a cumulative remote service time of more than 400,000 minutes.
After finding out the track, how should China's medical device market innovate? Wang Tao believes that "hard" and "soft" innovation should go hand in hand. Siemens medical device innovation and equipment sinking have basically been achieved and completed. In addition, the company has also been using technical means and platform functions to make high-quality medical resources, especially talent resources, land at the grassroots level.
Varian Zhang Xiao:
15 minutes of precision radiotherapy, China intelligent manufacturing services worldwide
Xiao Zhang, Senior Vice President of Varian Worldwide and President of Greater China
15 minutes of precise radiotherapy, automated contactless... This is varian's launch of the world's first artificial intelligence radiotherapy center in 2021. Varian is the world's first manufacturer to provide a total solution for proton oncology treatment, yes
A global leader in radiotherapy technology. In the past three years, with the efforts of Varian Greater China President Zhang Xiao and his team, the output of Varian's Beijing production site has increased by 6 times, and China is currently the most comprehensive R&D and production base in Varian's global product line.
Zhang Xiao told the People's Daily health client that Varian Medical, together with the Chinese industrial chain, has achieved a comprehensive transition from "copying global success to China" to "China's intelligent manufacturing services global", and Varian's Products in China base are currently 90% exported.
With the deepening of the health insurance reform, Zhang Xiao and his team have seen that in the past few years, China has significantly improved the accessibility of medical care, reduced the burden on patients, and improved the survival rate of cancer patients in China. This gives them a boost of confidence. Zhang Xiao said, "2022 is a new starting point for the new century, and we medical technology companies should seek development with innovation, patient-centered, value-oriented medical treatment, and enter a new era of medical technology." ”
So what innovations will Varyan take in 2022? Zhang Xiao introduced that Varian will increase investment in setting up an innovation center in China, on the one hand, to focus on digital and intelligent local innovation, and to provide digital and intelligent solutions covering the whole process of cancer diagnosis and treatment for China's national conditions. On the other hand, ecological partners within the United Nations have developed a new model of industrial collaboration of early screening, early diagnosis and early treatment, which has fundamentally changed the heavy cancer burden currently facing China.
In addition to technological innovation, Varian also pays attention to talent training. Walian will continue to support Chinese universities to carry out the "Radiotherapy Rising Star" medical public welfare project to attract more young forces to the clinic. At the same time, it will also work with the China Medical Equipment Association to jointly build China's first radiotherapy professional industry job competency training system "Radiotherapy Training Institute", and continue to support the China Cancer Foundation to carry out the public welfare project of "Grassroots Cancer Center Construction Training" to cultivate grassroots medical professionals.
Medtronic Gu Yushao:
Let the "black technology" in the field of medical devices realize localization in an all-round way
Yushao Gu, Senior Vice President of Medtronic Worldwide and President of Greater China
The world's smallest leadless pacemaker, the latest generation of transcatheter aortic valve replacement system, intelligent navigation robot for spine surgery... Every year Medtronic introduces innovative products. "Black technology" in the field of medical devices has often become synonymous with Medtronic's innovative products.
Why is Medtronic's "black technology" so prolific? Gu Yushao, senior vice president of Medtronic Global and president of Greater China, shared a case with a Tibetan uncle living in Metuo County, Tibet, who suffered from heart disease and had a pacemaker implanted in Chengdu. After the pacemaker is implanted, it is necessary to follow up regularly, test and adjust the various parameters of the pacemaker to ensure that the pacemaker works better. However, Metuo is located in a remote area, and it takes 2 days to go to the recent large hospital that can be followed up, and Metuo often blocks traffic due to ice or mudslides.
So the hospital prepared a "black technology" for the patient - a remote follow-up device for pacemakers. It is only the size of a mouse and can monitor and transmit data to the cloud 24 hours a day. Doctors can follow up patients remotely. Such a technology is a good solution to the inconvenience of patients in remote areas to follow up in central hospitals.
Similar "black technology" in 2022, Medtronic will also launch more innovative products. Gu Yushao said that under the action of multiple factors such as policy promotion, technology iteration, and market evolution, the innovation of medical technology is reshaping the future of the medical health industry. China is expected to become an important innovation base for the next generation of medical technology and solutions.
As a multinational medical technology enterprise rooted in China for more than 30 years, Gu Yushao frankly said, "Our first task at present is to think about how to promote Medtronic's localization strategy in an all-round way under China's new development pattern, and use innovative technology to benefit more people, not only leading innovation in China, but also making Medtronic's innovation in China go to the international stage and have a global impact." ”
ZEISS Liu Yonghua:
Over the next 5 years, we will increase our leading position in the field of refractive solutions
Liu Yonghua, Vice President of ZEISS China and General Manager of ZEISS Healthcare
ZEISS Healthcare is a leader in the field of ophthalmology, its inventions can be traced back to 1900, it was the pioneer of the category of fundus cameras, slit lamps and other equipment. In recent years, the sharp increase in zeiss medical performance in China has attracted much attention.
2022 is the 65th year of ZEISS' deep cultivation in the Chinese market, and in order to adapt to the development of the Chinese market, the "Five-Year Plan" has been formulated. In January 2022, the Health Commission issued the "14th Five-Year Plan for National Eye Health (2021-2025)", and in Liu Yonghua's view, policy support is a positive for the development of the industry.
Zeiss plans to increase its leadership in refractive solutions over the next five years, optimize comprehensive cataract solutions and build a network of cooperation with local partners to provide customized digital solutions.
As a multi-knowledge system comprehensive interdisciplinary discipline, ophthalmology is highly dependent on various equipment for the diagnosis and treatment of ophthalmology, and the quality of ophthalmic equipment determines the level of diagnosis and treatment to a certain extent. Liu Yonghua introduced that because of this, ZEISS has been continuously launching innovative equipment to meet the needs of clinicians, and is also trying to build a digital ophthalmic disease diagnosis and treatment network to help sink high-quality ophthalmology resources and benefit more patients.
In addition, the centenary of ZEISS, scientific and technological innovation and social responsibility is deeply rooted in its DNA of the tradition, in 2020 "full femtosecond smile China trip", for more than 1100 anti-epidemic doctors to Go to Hubei free of charge, in 2021 "full femtosecond smile Chinese model", for 615 role models from all walks of life free of charge, in 2022, the new journey set sail again, "full femtosecond science popularization into the campus" activity, will provide college students with authoritative scientific knowledge of eye health, work together with all parties to help healthy China.
Weisheng Pharmaceutical LuAnbang:
Endocrinology is the deep blue ocean of innovative drug discovery
Lu Anbang, CEO and Director of Weisheng Pharmaceutical
Lu Anbang has nearly 30 years of experience in the pharmaceutical industry, lu anbang is more concerned about where is the deep blue ocean in China's biomedical field?
"Endocrinology is the deep blue ocean of innovative drug discovery." Lu Anbang told the Health Times reporter that as a member of the innovative biomedical industry, taking clinical value as the center and trying to meet unmet clinical needs is the direction of our innovative development. There are more than 170 known endocrine diseases, many of which are not available in China or have limited efficacy of existing therapies. Meeting these unfulfilled clinical needs is what Viscount is trying to do.
It is not easy to develop new drugs in the field of endocrinology. Wei Sheng, on the other hand, went out of his way. At present, it has three drugs under research in the clinical stage, such as Longpei auxin is successfully advancing China's phase III clinical trials, and is expected to submit a listing application to the State Food and Drug Administration within 2022.
Talking about how China's pharmaceutical innovation can go from following to leading? Lu Anbang introduced, "We have just recently laid the foundation for the R&D and manufacturing base in Greater China in Suzhou, because building independent production capacity in China can flexibly and effectively accelerate the commercialization of pipeline products, which is a major measure for us to carry out the layout of the whole chain of innovative drugs." In the future, we will also transfer production technology and complete local production here. ”
Gauderma Red Rain:
"Beauty economy" boosts pharmaceutical innovation in the field of skin
Lei Hongyu, general manager of Gaodemei China
In recent years, thanks to the upgrading of public consumption and the boost of the "beauty economy", the skin health care industry in mainland China has entered a period of vigorous development, which includes three major areas: daily skin care, medical beauty and skin disease treatment.
As a company headquartered in Switzerland, Gao Demei has become a leader in this field. It is a company that provides comprehensive solutions that cover the full life cycle and use all scenarios.
As the head of Gaodemei China, Lei Hongyu introduced that 2021 is the first year for Gaodemei to practice the strategy of high-energy renewal in China, and at an unprecedented speed, Gaodemei will introduce the most advanced and highest quality innovative products to China. For example, with the support of the state's accelerated approval, in 2021 alone, Gao Demei was approved to list 4 medical aesthetic products and indications.
Speaking of innovation, Lei Hongyu shared the good news that Gao Demei's first innovative drug nemolizumab is being clinically tested as the first monoclonal antibody against IL-31 receptor α in the world, and is expected to help many troubled patients with atopic dermatitis and nodular prurigo regain their health in the near future.
In addition, it is expected that by 2024, Gaodemei will successively introduce about 9 medical aesthetic products, 6 skin care products for Chinese consumers and 1 heavy skin disease treatment product to meet the unmet skin health needs of consumers.